Budget 2023Budget 2023

Sun Pharma: Sustained traction in speciality to be a re-rating driver

Sun Pharma's India business is expected to gain traction as sub-chronic and acute therapies pick up with the opening up of clinics/OPDs. This is likely to be fully backed by the field force where the expansion has recently been completed

January 31, 2021 / 01:22 PM IST
Sun Pharma: Sustained traction in speciality to be a re-rating driver

Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Highlights - Q3 sales helped by US and India businesses - Improved margins mainly because of lower operating expenses and product mix - Few speciality products likely to break-even next fiscal - Heavy product launch pipeline to support India business India’s largest pharma company Sun Pharma (CMP: Rs 586 Market cap: Rs 140,649 crore) has posted two back to back strong quarters driven by speciality products. With the economy recovering, traction for even the US generic business has been better than expected and there has been market share...

  • PRO Panorama

    Moneycontrol Pro Panorama | Autos on the road to recovery

    Jan 25, 2023 / 03:44 PM IST

    In today’s edition of Moneycontrol Pro Panorama: Gland Pharma’s poor streak cause for concern, no signs of recovery for Colgat...

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender: The downsizing of Davos Man

    Jan 21, 2023 / 10:10 AM IST

    The World Economic Forum has been desperately trying to reinvent itself, but Davos Man’s heydays are a thing of the past

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers